Millions of individuals in the United States require long-term treatment with an oral
anticoagulant. For decades, vitamin K antagonists were the only oral option available; …

Cardiovascular diseases are highly prevalent among patients on dialysis. For these
diseases, antiplatelets and antithrombotic therapies including heparin, vitamin K …

Abstract Purpose of Review Cancer-related mortality has significantly declined over the past
several decades as a result of improved screening, diagnostics, and therapeutics. Although …

Aims This study compared the risk of major bleeding between atrial fibrillation (AF) patients
who took non-vitamin K antagonist oral anticoagulants (NOACs) and antiepileptic drugs …

Although preclinical research and observer studies on patients with atrial fibrillation
concluded that direct oral anticoagulants (DOACs) can protect against dementia like …

Background The risk of intracranial hemorrhage (ICH) in patients taking direct oral
anticoagulants (DOACs) after mild traumatic brain injury (MTBI) is unclear. Objectives To …

Background The percentage of elderly trauma patients under anticoagulation and
antiplatelet agents has been rising lately. As newer agents are introduced, each comes with …

Vitamin K epoxide reductase (VKOR), an endoplasmic reticulum membrane protein, is the
key enzyme for vitamin K–dependent carboxylation, a posttranslational modification that is …

Many healthcare resources have been and continue to be allocated to the management of
patients with COVID-19. Therefore, the ongoing care of patients receiving oral …

Importance The influence of race and ethnicity on initiation of direct oral anticoagulants
(DOACs) is relatively understudied in Medicare data. Objective To investigate disparities in …